Non-Insulin Therapies For Diabetes Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What CAGR Will the Non-Insulin Therapies For Diabetes Market Achieve During 2025–2034, and What Does It Indicate?
The market size for non-insulin diabetes treatments has seen a significant increase in the past few years. The market, which was worth $19.98 billion in 2024, is projected to expand to a value of $21.41 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this growth during the historic period include rising diabetes occurrence, improved understanding of diabetes management, increasing healthcare spending, lifestyle alterations leading to higher rates of incidence, a greater focus on diagnosis, increased governmental efforts towards diabetes care, and more investments in pharmaceutical research and development.
The market size for non-insulin diabetes treatments is predicted to experience substantial expansion in the coming years, reaching $27.9 billion in 2029 with a 6.8% Compound Annual Growth Rate (CAGR). Factors contributing to this growth in the forecasted period include the increasing incidence of diabetes, heightened consciousness about diabetes management, widespread acceptance of combination therapies, a growing elderly demographic, escalating healthcare spending, telemedicine development, and greater preference for oral medication. Notable trends forecast for this period encompass advancements in both oral and injectable prescriptions, progression in drug delivery systems, advancement in the delivery of oral peptides, the embracement of telemedicine and digital health solutions, and advances in combination therapies.
What Are the Primary Drivers Supporting the Growth of the Non-Insulin Therapies For Diabetes Market?
The rise in diabetes cases is anticipated to spur the development of non-insulin treatments in the diabetes market. Diabetes, a long-term health condition, is typified by elevated blood sugar levels, arising when the body is unable to produce sufficient insulin or use it correctly. Sedentary lifestyles, unhealthy food habits, genetic factors, an aging population, obesity, ethnicity, a lack of awareness, restricted healthcare access, and environmental influences all contribute to the rising incidence of diabetes. Non-insulin diabetic treatments work by enhancing insulin receptiveness, curbing liver glucose production, raising muscle cell glucose intake, and boosting overall blood sugar control. For instance, as reported by The British Diabetic Association in April 2023, around 4.3 million people in the UK were diagnosed with diabetes. Registration data from 2021-22 reveals an uptick of 148,951 cases relative to 2020-21. Additionally, over 2.4 million individuals in the UK are at an elevated risk of contracting type 2 diabetes. Hence, the rising prevalence of diabetes is bolstering the expansion of non-insulin treatments within the diabetes market.
Get Your Free Sample of the Global Non-Insulin Therapies For Diabetes Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
Who Are the Key Firms Paving the Way for Growth in the Non-Insulin Therapies For Diabetes Market?
Major companies operating in the non-insulin therapies for diabetes market are:
• Pfizer Inc._x000D_
• F. Hoffmann-La Roche AG_x000D_
• Merck & Co. Inc._x000D_
• Sanofi_x000D_
• The Bristol-Myers Squibb Company_x000D_
What Are the Most Influential Trends Currently Shaping the Non-Insulin Therapies For Diabetes Market?
Large firms active in the diabetes non-insulin therapies market are creating bespoke diabetes management systems. These systems aim to improve patient results by enabling real-time tracking, data analysis, and tailored treatment options. A personalized diabetes management system modifies the treatment and monitoring based on the individual needs of each patient. These alterations use real-time data and analytics to elevate care quality and outcomes. For example, in November 2022, Eli Lilly and Company, a pharmaceutical company based in the United States, introduced the Tempo personalized diabetes management platform. The platform is composed of three key features: the Tempo Smart Button, the TempoSmart application, and finally, the pre-loaded insulin pen known as the Tempo Pen. Together, these features create a synergistic effect, offering customized advice for adults living with diabetes. The technology is geared towards assisting adults dealing with type 1 or type 2 diabetes and their healthcare providers. It does so by enabling them to make educated, data-led decisions regarding the use of Lilly insulins in their treatment.
Get Instant Access to the Global Non-Insulin Therapies For Diabetes Market Report with Swift Delivery!
What Major Market Segments Define the Scope and Growth of the Non-Insulin Therapies For Diabetes Market?
The non-insulin therapies for diabetes market covered in this report is segmented –
1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications
Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
Which Regions Are Essential for the Growth of the Non-Insulin Therapies For Diabetes Market?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Elements Shape the Definition of the Non-Insulin Therapies For Diabetes Market?
Non-insulin therapies for diabetes refer to medications and treatments used to manage blood sugar levels in diabetic patients without the use of insulin injections. They are essential for regulating blood sugar levels in patients, who either do not need or prefer insulin injections.
Browse Through More Similar Reports By The Business Research Company:
Post-Traumatic Stress Disorder Therapeutics Global Market Report 2024
Insulin Patch Pumps Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report
Insulin biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
